Recent advances in anticancer ruthenium Schiff base complexes

Nowadays in cancer treatment, both metal complexes and organic molecules are being widely used. Current years have seen a surge of interest in the application of organometallic compounds to treat cancer and other diseases. Undeniably, the unique properties of organometallic compounds, intermediate between those of classical inorganic and organic materials, provide new opportunities in the field of medicinal chemistry. Since the discovery of cisplatin, many transition metal complexes have been synthesized and assayed for anticancer activity. In recent years, ruthenium-based Schiff base complexes have emerged as promising antitumor and antimetastatic agents with potential uses in treatment of platinum-resistant tumors or as alternatives to platinum-based chemotherapy. Advantages of utilizing ruthenium complexes in drug development include reliable methods of synthesizing stable complexes; the ability to tune ligand affinities, electron transfer and substitution rates, and reduction potentials; and an increasing knowledge of the biological effects of such complexes. This great expansion of ruthenium-based Schiff base complexes is mainly due to the unique ability of the ruthenium core to permit multiple oxidation states, hence versatile electron-transfer pathways, and because of the ease of preparation with versatile and variable-denticity Schiff base ligands. This review aims to bring the reader up to date with the more recent Ru(II)/(III)-based Schiff base complexes that have been synthesized and investigated for their cytotoxicity.     

DNA structural distortions induced by ruthenium-arene anticancer compounds

Organometallic ruthenium(II)-arene (RA) compounds combine a rich structural diversity with the potential to overcome existing chemotherapeutic limitations. In particular, the two classes of compounds [Ru(II)(eta(6)-arene)X(en)] and [Ru(II)(eta(6)-arene)(X)2(pta)] (RA-en and RA-pta, respectively; X = leaving group, en = ethylenediamine, pta = 1,3,5-triaza-7-phosphaadamantane) have become the focus of recent anticancer research. In vitro and in vivo studies have shown that they exhibit promising new activity profiles, for which their interactions with DNA are suspected to be a crucial factor. In the present study, we investigate the binding processes of monofunctional RA-en and bifunctional RA-pta to double-stranded DNA and characterize the resulting structural perturbations by means of ab initio and classical molecular dynamics simulations. We find that both RA complexes bind easily through their ruthenium center to the N7 atom of guanine bases. The high flexibility of DNA allows for fast accommodation of the ruthenium complexes into the major groove. Once bound to the host, however, the two complexes induce different DNA structural distortions. Strain induced in the DNA backbone from RA-en complexation is released by a local break of a Watson-Crick base-pair, consistent with the experimentally observed local denaturation. The bulkier RA-pta, on the other hand, bends the DNA helix toward its major groove, resembling the characteristic DNA distortion induced by the classic anticancer drug cisplatin. The atomistic details of the interactions of RA complexes with DNA gained in the present study shed light on some of the anticancer properties of these compounds and should assist future rational compound design.     

Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy

The antitumour activity of the organometallic ruthenium(ii)-arene mixed phosphine complexes, [Ru(eta(6)-p-cymene)Cl(PTA)(PPh(3))]BF(4) and [Ru(eta(6)-C(6)H(5)CH(2)CH(2)OH)Cl(PTA)(PPh(3))]BF(4) (PTA = 1,3,5-triaza-7-phosphaadamantane), have been evaluated in vitro and compared to their RAPTA analogues, [Ru(eta(6)-p-cymene)Cl(2)(PTA)] and [Ru(eta(6)-C(6)H(5)CH(2)CH(2)OH)Cl(2)(PTA)] . The results show that the addition of the PPh(3) ligand to increases the cytotoxicity towards the TS/A adenocarcinoma cancer cells, which correlates with increased uptake, but also increases cytotoxicity to non-tumourigenic HBL-100 cells, thus decreasing selectivity. The decrease in selectivity has been correlated to increased DNA interactions relative to proteins, demonstrated by reactivity of the compounds with a 14-mer oligonucleotide and the model proteins ubiquitin and cytochrome-c.     

Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis

With a view to develop drugs that could resist hydrolysis in aqueous media, organometallic arene-capped ruthenium(II) 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (RAPTA) complexes bearing chelating carboxylate ligands have been prepared and studied. The new complexes, Ru(eta6-cymene)(PTA)(C2O4) (1) and Ru(eta6-cymene)(PTA)(C6H6O4) (2), were found to be highly soluble and kinetically more stable than their RAPTA precursor that contains two chloride ligands in place of the carboxylate ligands. They were also able to resist hydrolysis in water and exhibited significantly lower pKa values. Importantly, they showed a similar order of activity in inhibiting cancer cell-growth proliferation (as determined by in vitro assays) and exhibited oligonucleotide binding characteristics (as evidenced by matrix-assisted laser desorption ionization mass spectrometry) similar to those of the RAPTA precursor, hence realizing a strategy for developing a new generation of stable and highly water-soluble RAPTA adducts.     

Designing organometallic compounds for catalysis and therapy

Bioorganometallic chemistry is a rapidly developing area of research. In recent years organometallic compounds have provided a rich platform for the design of effective catalysts, e.g. for olefin metathesis and transfer hydrogenation. Electronic and steric effects are used to control both the thermodynamics and kinetics of ligand substitution and redox reactions of metal ions, especially Ru(II). Can similar features be incorporated into the design of targeted organometallic drugs? Such complexes offer potential for novel mechanisms of drug action through incorporation of outer-sphere recognition of targets and controlled activation features based on ligand substitution as well as metal- and ligand-based redox processes. We focus here on η(6)-arene, η(5)-cyclopentadienyl sandwich and half-sandwich complexes of Fe(II), Ru(II), Os(II) and Ir(III) with promising activity towards cancer, malaria, and other conditions.     

Analytical potential of fullerene as adsorbent for organic and organometallic compounds from aqueous solutions

In this work, the analytical potential of C60 fullerene as a sorbent for organic and organometallic compounds from aqueous solutions was studied for the first time. Fullerene adsorbs many types of organic substances (e.g., N-methylcarbamates, phenols, polycyclic aromatic hydrocarbons, amines) with efficiencies that depend on the nature of the compound concerned and never exceed 60%. Conventional sorbents such as XAD-2 or polyurethane foam are more efficient than C60 for this purpose. Organometallic compounds (viz. metalocenes and organoleads) are quantitatively adsorbed on C60 via the formation of neutral complexes or chelates; the adsorption constant is dramatically increased by the use of classical reagents such as pyrrolidinedithiocarbamate or diethyldithiocarbamate. A complementary comparative study on the adsorption of organometallic complexes on RP-C18 and silica gel 100, among others, showed C60 to be superior as sorbent. All experiments in this work were carried out by using continuous flow configurations and gas chromatography-atomic absorption spectrometry techniques.     

Biometallorganische Chemie: Ein faszinierendes Forschungsgebiet

Bioorganometallic Chemistry is a new research area in which organometallic compounds are coupled with biomolecules (sugars, peptides, DNA and its constituents, steroides, vitamines, enzymes). In a narrow sense such organometallic complexes occur in nature (vitamin B₁₂), have a biological function (e.g. nickel enzymes in bacterias) or are of potential medical use (as novel drug or as marker for biomolecules). In a wider sense bioorganometallic chemistry includes simply metal complexes which besides organometallic ligands (e.g. CO, π‐hydrocarbon) have a biomolecule as ligand (e.g. with interesting structures, for catalysis).     

Planar chiral (η5-cyclohexadienyl)- and (η6-arene)-tricarbonylmanganese complexes: synthetic routes and application

Planar chiral arenetricarbonylchromium complexes have been intensively investigated and they have been applied as valuable building blocks for asymmetric synthesis and as ligands for asymmetric catalysis. In contrast, in the field of the isoelectronic cationic [(η(6)-arene)Mn(CO)(3)](+) complexes, until these last 10 years, very few studies were published involving nonracemic planar chiral cationic complexes and their potential applications, certainly because of the difficult access to enantiopure starting material. In 2009, however, the discovery of the first resolution of such compounds opened a new area for their application in the field of organic as well as of organometallic enantioselective syntheses. We felt it important to write a review on this subject to give an up-to-date summary of the methodologies used to prepare enantiomerically pure planar chiral neutral [(η(5)-cyclohexadienyl)Mn(CO)(3)] and cationic [(η(6)-arene)Mn(CO)(3)](+) complexes as well as their potential in enantioselective synthesis.     

Recent Advances in the Biological Investigation of Organometallic Platinum-Group Metal (Ir,Ru, Rh,Os, Pd,Pt) Complexes as Antimalarial Agents

In the face of the recent pandemic and emergence of infectious diseases of viral origin, research on parasitic diseases such as malaria continues to remain critical and innovative methods are required to target the rising widespread resistance that renders conventional therapies unusable. The prolific use of auxiliary metallo-fragments has augmented the search for novel drug regimens in an attempt to combat rising resistance. The development of organometallic compounds (those containing metal-carbon bonds) as antimalarial drugs has been exemplified by the clinical development of ferroquine in the nascent field of Bioorganometallic Chemistry. With their inherent physicochemical properties, organometallic complexes can modulate the discipline of chemical biology by proffering different modes of action and targeting various enzymes. With the beneficiation of platinum group metals (PGMs) in mind, this review aims to describe recent studies on the antimalarial activity of PGM-based organometallic complexes. This review does not provide an exhaustive coverage of the literature but focusses on recent advances of bioorganometallic antimalarial drug leads, including a brief mention of recent trends comprising interactions with biomolecules such as heme and intracellular catalysis. This resource can be used in parallel with complementary reviews on metal-based complexes tested against malaria.     

Photochromism of organometallic compounds with structural rearrangement

This article introduces photochromic properties together with structures of organometallic compounds that undergo photo-induced structural rearrangement. The aim of this review is to survey the research on photochromism by using organometallics which possess by their own nature the properties responsible for the photochromism such as bonding and structural fluxionality, electronic state fluctuation, and photochemically active characteristic in both solution and the solid state. Therefore, the organometallics which include the well-characterized organic photochromic moieties, considered to be derivatives of such kinds of organic photochromic compounds, are excluded in this article. Mono-, di-, and poly-nuclear organometallic compounds are presented based on the reaction types such as linkage isomerization, haptotropic rearrangement, and reorganization of metal–ligand and/or metal–metal bonds. Very recently, the crystalline-state photochromism is becoming an attractive field of photochromic chemistry. As a demonstrative example, the photochromism of organometallic rhodium dinuclear complexes having a dithionite ligand (μ-O₂SSO₂), which shows 100% reversible interconversion in the crystalline-state and have been developed in the authors’ laboratory, will be discussed.     

Copper(II) Phenanthroline-Based Complexes as Potential AntiCancer Drugs: A Walkthrough on the Mechanisms of Action

Copper is an endogenous metal ion that has been studied to prepare a new antitumoral agent with less side-effects. Copper is involved as a cofactor in several enzymes, in ROS production, in the promotion of tumor progression, metastasis, and angiogenesis, and has been found at high levels in serum and tissues of several types of human cancers. Under these circumstances, two strategies are commonly followed in the development of novel anticancer Copper-based drugs: the sequestration of free Copper ions and the synthesis of Copper complexes that trigger cell death. The latter strategy has been followed in the last 40 years and many reviews have covered the anticancer properties of a broad spectrum of Copper complexes, showing that the activity of these compounds is often multi factored. In this work, we would like to focus on the anticancer properties of mixed Cu(II) complexes bearing substituted or unsubstituted 1,10-phenanthroline based ligands and different classes of inorganic and organic auxiliary ligands. For each metal complex, information regarding the tested cell lines and the mechanistic studies will be reported and discussed. The exerted action mechanisms were presented according to the auxiliary ligand/s, the metallic centers, and the increasing complexity of the compound structures.     

Bioactive Luminescent Transition‐Metal Complexes for Biomedical Applications

The serendipitous discovery of the anticancer drug cisplatin cemented medicinal inorganic chemistry as an independent discipline in the 1960s. Luminescent metal complexes have subsequently been widely applied for sensing, bio‐imaging, and in organic light‐emitting diode applications. Transition‐metal complexes possess a variety of advantages that make them suitable as therapeutics and as luminescent probes for biomolecules. It is thus highly desirable to develop new luminescent metal complexes that either interact with DNA through different binding modes or target alternative cellular machinery such as proteins as well as to provide a more effective means of monitoring disease progression. In this Review, we highlight recent examples of biologically active luminescent metal complexes that can target and probe a specific biomolecule, and offer insights into the future potential of these compounds for the investigation and treatment of human diseases.     

Development of organometallic (organo‐transition metal) pharmaceuticals

This paper is aimed at introducing the organometallic chemist to the fascinating area of organometallic pharmaceuticals. It commences by identifying the properties of organometallic (transition metal) compounds that lend themselves to medical applications. Next, the specialized techniques and methods that are used to assess the medicinal properties of compounds are summarized, and although these techniques are not restricted to organometallic compounds, all examples are concerned with organometallic compounds. The design and evaluation of organometallic compounds for medicinal applications are described in context with the diseases they have been evaluated against, and areas are identified that may have most potential for organometallic pharmaceuticals. Some new results, including the first example of an organo‐osmium compound that might exhibit effective anticancer properties, are also described. Copyright © 2005 John Wiley & Sons, Ltd.     

Adding diversity to ruthenium(II)-arene anticancer (RAPTA) compounds via click chemistry: The influence of hydrophobic chains

The application of click chemistry to develop libraries of organometallic ruthenium-arene complexes with potential anticancer properties has been investigated. A series of ruthenium-imidazole-triazole complexes, with hydrophobic tails, were prepared from a common precursor via click chemistry. The tail could be attached to the ligand prior to coordination to the ruthenium complex or following coordination, the former giving the product in superior yield. The complexes were screened for cytotoxicity in tumourigenic and non-tumourigenic cell lines, and while the compounds were only moderately cytotoxic, good selectivity for tumourigenic cells was observed.     

Nickel and palladium <Emphasis Type="Italic">N</Emphasis>-heterocyclic carbene complexes. Synthesis and application in cross-coupling reactions

N-Heterocyclic carbenes (NHCs) are widely used as ligands in catalysis by transition metal complexes. The catalytic activity of transition metal NHC complexes is much higher than that of the transition metal complexes bearing the phosphine and nitrogen-containing ligands. They show excellent catalytic performance in different transformations of the organic compounds, especially in the carbon—carbon and carbon—element bond forming reactions. Palladium NHC complexes are very efficient catalysts for the cross-coupling reactions. On the other hand, nickel is less expensive and regarded as a promising alternative to palladium and, therefore, it attracts increasing attention from the researches. The present review is focused on the recent advances in the synthesis of N-heterocyclic carbene complexes of nickel and palladium and their application in catalysis of cross-coupling reactions of organic, organoelement and organometallic compounds with organic halides.     

Am(m)ines Make the Difference: Organoruthenium Am(m)ine Complexes and Their Chemistry in Anticancer Drug Development

With the aim of systematically studying fundamental structure–activity relationships as a basis for the development of Ru^II arene complexes (arene=p‐cymene or biphenyl) bearing mono‐, bi‐, or tridentate am(m)ine ligands as anticancer agents, a series of ammine, ethylenediamine, and diethylenetriamine complexes were prepared by different synthetic routes. Especially the synthesis of mono‐, di‐, and triammine complexes was found to be highly dependent on the reaction conditions, such as stoichiometry, temperature, and time. Hydrolysis and protein‐binding studies were performed to determine the reactivity of the compounds, and only those containing chlorido ligands undergo aquation or form protein adducts. These properties correlate well with in vitro tumor‐inhibiting potency of the compounds. The complexes were found to be active in anticancer assays when meeting the following criteria: stability in aqueous solution and low rates of hydrolysis and binding to proteins. Therefore, the complexes least reactive to proteins were found to be the most cytotoxic in cancer cells. In general, complexes with biphenyl as arene ligand inhibited the growth of tumor cells more effectively than the cymene analogues, consistent with the increase in lipophilicity. This study highlights the importance of finding a proper balance between reactivity and stability in the development of organometallic anticancer agents.     

Pyrazine based Pt(II) bis‐alkynyl organometallic complexes: Synthesis,characterization, and cytotoxic effect on A549 human lung carcinoma cells

A facile and efficient synthesis of a series of five new pyrazine‐based organometallic complexes is being reported. The complexes ( 2 – 6 ) have been fully characterized. Molecules 2 , 3 and 6 were structurally characterized by single crystal X‐ray crystallographic analyses. Additionally, anticancer properties of these organometallic complexes have been studied against A549 human lung carcinoma cells. Biological studies suggest that complex 5 (with pendant pyridine moieties) exhibited maximal growth inhibitory cytotoxic effect even at lower concentration (nearly 0.5–1 μM) whereas the other four compounds ( 2 , 3 , 4 and 6 ) were non‐toxic below 1 μM concentration. Two complexes ( 4 and 6) were effective only at higher doses (approx 30 μM) while the remaining two organometallic complexes ( 2 and 3) were able to inhibit 50% cell growth at slightly lower concentration (nearly 10 μM). As far as IC₅₀ is concerned, 5 exhibited a minimum value ranging between 3–5 μM which is comparable with cisplatin under similar conditions.     

Phosphorus Ylides in the Coordination Sphere of Transition Metals: An Inventory

Phosphorus ylides are not only classical reagents in organic chemistry, but also play an increasingly important role as novel components in organometallic compounds. These metallic “ylide complexes” are either synthesized from “preformed ylides” and coordination compounds by addition or substitution, on the building block principle, or they are formed, in sometimes complicated reactions, from phosphanes, metal complexes, and C₁ substrates in the coordination sphere of the metals. The resulting metal-carbon bonds are greatly modified in their properties by the immediate presence of the phosphonium center and often belong to the most stable of M-C structural units. The metal can come from any group of the periodic table, including the lanthanoids and actinoids. Numerous preparative and structural studies are gradually enabling us to gain an overall picture of the scope of this area of research.     

新型含N-杂环卡宾二硫化碳配体的锰铼金属双核化合物的合成、表征及电化学性质简

合成了一系列含N-杂环卡宾二硫化碳加合物配体的锰铼金属有机化合物,其中包括3种单核化合物和3种双核化合物,对它们的结构进行了表征,并研究其反应性和电化学性质. 与三烷基膦二硫化碳配体相比,含N-杂环卡宾二硫化碳加合物配体的锰铼金属有机化合物展现出不同的反应特性. 研究结果表明,[MnRe(CO)6(μ-H){μ-CH3SC(S)IMes2}]配合物具有催化质子还原成氢气的能力.     

Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity

Potential biological and medical applications of organometallic complexes are hampered by a lack of knowledge of their aqueous solution chemistry. We show that the hydrolytic and aqueous solution chemistry of half-sandwich OsII arene complexes of the type [(eta6-arene)Os(XY)Cl] can be tuned with XY chelating ligands to achieve cancer cell cytoxicity comparable to carboplatin. Complexes containing arene = p-cymene, XY = N,O-chelating ligands glycinate (1), L-alaninate (2), alpha-aminobutyrate (3), beta-alaninate (4), picolinate (5), or 8-hydroxyquinolinate (7) were synthesized. Although, 1-4 and 7 hydrolyzed rapidly (相似文献